CA Technologies, a Fortune 500 company headquartered in Islandia, NY, has agreed to pay $11 million to settle whistleblower allegations that the software giant violated the federal False Claims Act and similar state and local statutes through the fraudulent billing of hundreds of public agencies on software maintenance renewal contracts from 2001 through 2009, according to court documents unsealed today.
November 12, 2013. Read more.
The U.S. Department of Justice announced that it had finalized an agreement with pharmaceutical giant Johnson & Johnson (J&J) to resolve for $2.2 billion certain criminal and civil claims arising from the company’s alleged illegal marketing of the atypical antipsychotic drug, Risperdal. This settlement resolved a number of qui tam cases brought under the False Claims Act, and included a $149 million payment to resolve a qui tam action brought by a Vogel, Slade & Goldstein client against J&J and Omnicare, the nation’s largest long term care pharmacy chain, based on alleged kickback transactions between the two companies that were designed to increase Risperdal sales to the residents of the nursing homes serviced by Omnicare.
November 4, 2013. Read more.
Rob Vogel, Shelley Slade & Janet Goldstein of the national qui tam law firm Vogel, Slade & Goldstein, LLP, have been named the 2013 “Whistleblower Lawyers of the Year” by Taxpayers Against Fraud, the preeminent public interest organization dedicated to combating fraud against the government. At its annual Awards Dinner on October 24, 2013 in Washington, D.C., TAF announced that it had selected all three principals of Vogel, Slade & Goldstein as whistleblower lawyers of the year for their significant and groundbreaking work on two whistleblower cases that resolved in 2013. TAF described the three partners as “super achievers“ who have been “at the forefront of False Claims Act litigation from the start” and who have “shaped qui tam law practice over the past two decades.”
November 4, 2013. Read more.
Janet Goldstein spoke about litigating qui tam cases under the False Claims Act at a National Employment Lawyers Association (NELA) conference entitled Shining the Light on Whistleblower & Retaliation Claims.
October 18, 2013. Read more.
Pfizer Inc, the owner of Wyeth Pharmaceuticals Inc., finalized its agreement to pay $491 million to resolve the allegations in a whistleblower lawsuit against Wyeth filed in 2007 by Vogel, Slade & Goldstein, LLP, on behalf of Mark Campbell, a former Wyeth sales representative, that alleged that Wyeth for over a decade illegally marketed the transplant drug Rapamune for uses that had not been approved by the U.S. Food & Drug Administration.
July 30, 2013. Read more.
The Gallup Organization has agreed to pay $10.5 million to settle allegations in a qui tam lawsuit filed by whistleblower Michael Lindley that Gallup violated the False Claims Act for conduct involving several of its federal government contracts and subcontracts.
July 15, 2013 Read More.
Shelley R. Slade testified at a congressional hearing concerning the law and procedures pertaining to U.S. Department of Justice decisions on whether to intervene in False Claims Act qui tam cases.
May 7, 2013 Read More.
Janet Goldstein spoke on the False Claims Act at the Health Care Compliance Association’s 17 the Annual Compliance Institute. The 5-day conference was held in Washington, D.C., beginning April 21, 2013. The 3-hour panel entitled False Claims Act Developments covered a variety of topics including qui tam and retaliation actions, and relators’ rewards.
April 21, 2013
Rob Vogel co-chaired a CLE conference on qui tam cases and the False Claims Act, at the Hotel Nikko in San Francisco on April 18-19, 2013. The conference featured panelists from U.S. Attorney’s Offices, State Attorney General’s Offices, JAMS, Stanford Law School, and leading law firms across the United States.
April 18-19, 2013
Shelley Slade taught a class at Cornell Law School on the “first-to-file” provision in the federal False Claims Act. Launched by the Dean of Cornell Law School in conjunction with a practicing qui tam attorney, the course utilizes the first-ever, major law school syllabus dedicated exclusively to the False Claims Act and relies on regular guest speakers from the government, defense bar and qui tam bar.
February 18, 2013.
Former FEMA executive Timothy Cannon pleaded guilty to a felony conflict of interest charge for steering a FEMA contract and funding to Gallup while he was negotiating a partnership position with the worldwide polling firm. The criminal charge arises from a qui tam lawsuit that Vogel, Slade & Goldstein and Katz, Marshall & Banks filed against Gallup on behalf of their client, Michael Lindley in 2009.
January 15, 2013. Read More.
The United States Department of Justice filed a felony conflict of interest charge against former FEMA Executive Timothy Cannon for corrupty steering contracts and funding to Gallup. The charges arise from a whistleblower lawsuit against Gallup by VS&G client Michael Lindley.
January 2, 2013. Read More.
The U.S. Department of Justice has intervened in the qui tam lawsuit that whistleblower law firms Vogel, Slade & Goldstein and Katz, Marshall & Banks have filed against The Gallup Organization on behalf of their client, Michael Lindley. November 28, 2012. Read More.
Robert Vogel, co-chair of the Procurement Fraud Committee of the ABA Section of Public Contract Law, moderated a panel discussion in Washington, DC. The topic was recent court decisions in False Claims Act cases brought by qui tam whistleblowers. The panelists included Michael Granston, Acting Director of the Commercial Fraud Section, Civil Division, U.S. Department of Justice.
October 18, 2012
Janet Goldstein was reappointed as a national co-chair of the Qui Tam Subcommittee of the American Bar Association, Criminal Justice Section, for a two year term.
September 24, 2012
Shelley Slade was a panelist on a “False Claims Act 101” Panel at the Taxpayers Against Fraud Education Fund 12th Annual Conference in Washington, D.C. The panel trained new qui tam attorneys on the basics of False Claims Act jurisprudence and practice.
September 12, 2012
Robert Vogel participated on the panel “The False Claims Act-Broadening the Use of the False Claims Act to Address Perceived Procurement Waste, Abuse and Fraud” at the Practicing Law Institute, Government Contracts 2012 (Washington, DC), September 20, 2012.
Shelley Slade participated on the panel “The Rise of Qui Tam Litigation and its Impact on How Fraud Cases are Investigated and Prosecuted” at the Edward Bennett Williams’ American Inns of Court Meeting (Washington, D.C.). Her co-panelists included Joyce Branda, Acting Deputy Assistant Attorney General, U.S. Department of Justice; Gary Giampetruzzi, Assistant General Counsel & Chief of Government Investigations, Pfizer; and, Brien O’Connor, Partner, Ropes & Gray.
September 20, 2012.
The United States Department of Justice Joined A Qui Tam Lawsuit Against The Gallup Organization filed in federal district court in Washington, D.C. brought by VS&G client Michael Lindley.
August 24, 2012. Read more.
Shelley Slade was quoted in an article entitled “GSK Ills Symptomatic of Wider Malaise” in the Financial Times, on the topic of how best to deter off-label sales pitches, kickbacks and other marketing misconduct by pharmaceutical companies. Ms. Slade argued that only criminal action against the individual executives who set these schemes in motion will bring lasting reform.
July 6, 2012.
In a June 8, 2012 press release, Johnson & Johnson stated it is taking a $600 million charge for settlement of cases involving J&J kickbacks to long term care pharmacy chain Omnicare to increase sales of Risperdal and two other drugs. VS&G represents the whistleblower in one of the two qui tam cases against J&J for paying kickbacks to Omnicare to promote Risperdal.
June 9, 2012.
Robert Vogel participated in a panel discussion of “Settlements of Government Procurement Cases” at the ABA National Institute on the Civil False Claims Act and Qui Tam Enforcement in Washington, DC.
June 8, 2012.
Janet Goldstein moderated a panel discussion on “Litigating False Claims Act Cases” and co-led the “Qui Tam Attorneys Workshop” at the ABA National Institute on Health Care Fraud in Las Vegas, NV.
May 9-11, 2012.
Robert Vogel, co-chair of the Procurement Fraud Committee of the ABA Public Contract Law Section, moderated a panel on “Negotiating Settlements in Procurement Fraud Cases” in Washington, DC. Included in the panel were Brian Miller, Inspector General of the General Services Administration, and Judith Rabinowitz, an Assistant Director of the Civil Frauds Section of the U.S. Department of Justice.
May 9, 2012
Shelley Slade was quoted in an article in the Wall Street Journal on settlement negotiations to resolve allegations that Johnson & Johnson unlawfully marketed the antipsychotic drug Risperdal.
March 13, 2012.
Robert Vogel participated in a panel discussion of “Implied Certification under the False Claims Act” at the ABA Federal Procurement Institute in Annapolis, MD.
March 22-23, 2012.
Shelley Slade, as a member of the Board and Executive Committee of the non-profit Taxpayers Against Fraud, presented the Honest Abe Integrity in Government award to Michael F. Hertz, who, at the time, was the Deputy Assistant Attorney General for the Civil Division of the U.S. Department of Justice. In her remarks, Ms. Slade noted that Mr. Hertz has steered the government’s enforcement of the FCA with exceptional integrity, fairness, brilliance and fearlessness for 30 years. Mr. Hertz sadly passed away in April 2012.
News Archive Highlights
August 3, 2011
Rob Vogel of Vogel, Slade & Goldstein Comments on SEC Proposed Rule.
July 7, 2011
Armor Group North America and its Affiliates Pay $7.5 Million to Resolve False Claims Act Allegations.
September 21, 2010
Bringing its False Claims Act Settlements in VS&G Lawsuits to a Total of $197.5, Omnicare Pays $21 million to Settle Allegations of Medicaid Fraud in Massachusetts and Michigan in Whistleblower Action. Read more
November 3, 2009
Ivax Pharmaceuticals to Pay $14 Million to Resolve False Claims Act Lawsuit.
May 18, 2009
False Claims Act Amendments Passed By Congress; Qui Tam attorney Shelley Slade Provides Key Testimony Before Congress.